The effects of blocking angiotensin receptors on early stages of diabetic nephropathy

The effects of blocking angiotensin receptors on early stages of diabetic nephropathy

Background: This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). Methods: This cross-sectional study was conducted on 32 participants with IDDM from January 2010 un...

Full description

Bibliographic Details
Main Authors:	Alaleh Gheissari, Shaghayegh H Javanmard, Roohollah Shirzadi, Masood Amini, Nooshin Khalili
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2012-01-01
Series:	International Journal of Preventive Medicine
Subjects:	Angiotensin receptor blocker diabetic nephropathy endothelial dysfunction valsartan
Online Access:	http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=7;spage=477;epage=482;aulast=Gheissari

Similar Items

Effect of Angiotensin Receptor Inhibitors on Endothelial Dysfunction
by: Alaleh Gheisari, et al.
Published: (2011-10-01)

Nephroprotective effect of vitamin E added to angiotensin receptor blocker in patients with diabetic nephropathy
by: Abdulrazzaq Alkaaby, et al.
Published: (2021-12-01)

Effect of the Renin-Angiotensin-Aldosterone System Reactivity on Endothelial Function and Modulative Role of Valsartan in Male Subjects with Essential Hypertension
by: Jakub Jasiczek, et al.
Published: (2021-12-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
by: Po‐Cheng Chang, et al.
Published: (2020-10-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
by: Dan-Dan Qiu, et al.
Published: (2018-01-01)

Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
by: Rodolfo Pedro Rothlin, et al.
Published: (2021-03-01)

Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW)
by: Pınar Kızılırmak, et al.
Published: (2014-06-01)

Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
by: Yu ZHAO, et al.
Published: (2019-09-01)

CARDIOVASCULAR PATIENT WITH STAGE 1-3 CHRONIC KIDNEY DISEASE: CONTEMPORARY CARDIONEPHROPROTECTION IN REAL CLINICAL PRACTICE
by: E. I. Tarlovskaya
Published: (2016-09-01)

Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis
by: Zexu Wang, et al.
Published: (2023-01-01)

Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers
by: David S. Fedson, et al.
Published: (2015-07-01)

Comparing the Efficacy of Angiotensin Converting Enzyme Inhibitors with Calcium Channel Blockers on the Treatment of Diabetic Nephropathy: A Meta-Analysis
by: Zhaowei ZHANG, et al.
Published: (2019-02-01)

Perspectives of using angiotensin receptor antagonists
by: V V Fomin
Published: (2009-06-01)

Efficacy of traditional Chinese medicine versus angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and their combinations in the treatment of IgA nephropathy: a systematic review and network meta-analysis
by: Sijia Ma, et al.
Published: (2024-03-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria
by: Yuanyuan Guo, et al.
Published: (2021-01-01)

Sartans: differences, similitudes and costs
by: Orietta Zaniolo, et al.
Published: (2008-06-01)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
by: Yebei Li, et al.
Published: (2021-11-01)

Transforming growth factor-β in diabetic nephropathy
by: Karima Y. Ahmed, et al.
Published: (2013-01-01)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
by: Tenenbaum Alexander, et al.
Published: (2002-04-01)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01)

ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

Effect of telmisartan, angiotensin‐converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs
by: Brittany L. Fowler, et al.
Published: (2021-05-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System
by: Graham J. Moore, et al.
Published: (2022-07-01)

Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
by: Eva Vivian, et al.
Published: (2013-03-01)

Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: insights from panvascular diseases
by: Xiaoqian Zhang, et al.
Published: (2024-02-01)

Regulation of Monocytes/Macrophages by the Renin–Angiotensin System in Diabetic Nephropathy: State of the Art and Results of a Pilot Study
by: Claudine Moratal, et al.
Published: (2021-06-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/β-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up
by: Xuhe Gong, et al.
Published: (2018-12-01)

Application of Meldonium for the Treatment of Patients with Diabetic Nephropathy
by: Topchii І.
Published: (2013-09-01)

Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
by: Imdat Eroğlu, et al.
Published: (2020-07-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials
by: Ruxin Wang, et al.
Published: (2022-12-01)